MYCN-amplified samples express high levels of the H3K9 histone-lysine methytransferases EHMT and EZH2, which directly contribute to low expression of CXCL9 and CXCL10 and a non-T cell-inflamed phenotype in primary tumor transcriptomic data as well as in human NBL cells, and can be reversed by targeted EHMT and EZH2 inhibitors (52). This evidence concerns the gene MYCN and neoplasm.